Compare Merck & Co., Inc. (MRK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sprott Uranium Miners ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Sprott Uranium Miners ETF trades at $50.32. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Sprott Uranium Miners ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MRK | URNM | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $83.99 |
52-Week Low | $77.60 | $44.14 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
URNM trades at $48.25 with minimal daily movement (+0.06%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI suggests potential oversold conditions. Recent news highlights uranium's role in AI power demand, with nuclear energy positioned as a solution to data center electricity needs. The fund has gained significant attention for its pure-play uranium miner exposure versus broader nuclear ETFs.
The uranium sector faces a favorable long-term outlook with projected nuclear demand tripling by 2050, though current technical weakness and concentration risks in mining companies present near-term challenges. URNM offers leveraged exposure to uranium price movements but remains vulnerable to sector volatility and supply chain constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
